

August 4, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2025.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2025.

Please take the information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithriviham, Ameerpet, Hyderabad-500038, Telangana, India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Press Release

Investor Relations | Corporate Communications
Phone: 040-66721211
Email: ir@aurobindo.com

Hyderabad, India, August 04th, 2025: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended June 30, 2025.

Aurobindo Pharma Limited Q1FY26

Amount (INR Cr)	Q1 FY26	Q1 FY25	%Change YoY	Q4 FY25	%Change QoQ
Revenue from Operations	7,868	7,567	4.0%	8,382	-6.1%
EBITDA before R&D	1,947	1,936	0.6%	2,202	-11.6%
EBITDA margin before R&D	24.8%	25.6%	-84 bps	26.3%	-152 bps
EBITDA before Forex and Other Income	1,603	1,620	-1.0%	1,792	-10.5%
EBITDA Margin (%)	20.4%	21.4%	-102 bps	21.4%	-100 bps
PBT before share of P/L of JV, Forex, and Exceptional items	1,205	1,324	-9.0%	1,356	-11.1%
Net Profit for the period	824	918	-10.2%	903	-8.7%

Key Highlights of Q1FY26

- Revenue from Operations increased by 4.0% YoY to INR 7,868 Cr with growth in Europe and Growth markets
- US formulations revenue marginally declined by 1.9% YoY to INR 3,488 Cr (USD 408 million)
- Europe formulations revenue increased by 18.0% YoY to INR 2,338 Cr (EUR 241 million)
- Growth Markets revenue increased by 8.8% YoY to INR 772 Cr (USD 90 million)
- ARV revenue increased by 55.2% YoY to INR 355 Cr (USD 41 million)
- API revenue decreased by 16.% YoY to INR 916 Cr (USD 107 million)
- EBITDA before R&D stood at INR 1,947 crores with a margin of 24.8%
- EBITDA before Forex and Other Income stood at INR 1,603 Cr; EBITDA margin at 20.4%
- Research & Development (R&D including depreciation) spend was INR 367 Cr, 4.7% of revenues
- Received final approval for 14 ANDAs (including 1 ANDA previously tentatively approved, now receiving the final approval) from the USFDA
- Net Profit for the period stood at INR 824 Cr
- Basic & Diluted EPS stood at INR 14.20 per share
- Board has approved interim dividend @ 400% i.e. INR 4.0 per equity share of INR 1/- for the year FY25-26

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "We started the year steadily, with our European business maintaining strong growth momentum and our core US business showing resilience despite temporary challenges from destocking and seasonal dynamics. Our disciplined execution, operational initiatives, and recent US acquisition strengthens our commercial footprint and accelerates growth potential."



Operational Performance (Consolidated)

₹ Cr	Q1FY26	Q1FY25	Y-o-Y (%)	Q4FY25	Q-o-Q (%)
USA	3,488	3,555	-1.9%	4,072	-14.3%
Europe	2,338	1,982	18.0%	2,147	8.9%
Growth Markets	772	709	8.8%	786	-1.8%
ARV	355	229	55.2%	308	15.2%
Total Formulations	6,953	6,475	7.4%	7,313	-4.9%
Beta-lactam	633	791	-20.0%	789	-19.8%
Non Beta-lactam	283	301	-6.0%	280	1.0%
Total API	916	1,092	-16.1%	1,069	-14.4%
Consolidated Sales (Ex- Puerto Rico)	7,868	7,567	4.0%	8,382	-6.1%
Puerto Rico	-	-	-	-	-
Revenue from operations	7,868	7,567	4.0%	8,382	-6.1%

*Includes domestic formulation sales of INR 71 Cr in Q1FY26

Q1FY26: Consolidated Revenue Breakup - Geography & Business wise

Q1FY26



Q1FY26 Performance

Formulations revenue increased by 7.4% YoY to INR 6,953 Cr.

US Formulations

- US revenue marginally decreased by 1.9% YoY to INR 3,488 Cr and accounted for 44.3% of consolidated revenue
- In USD terms, revenue decreased by 4.3% YoY to USD 408 million
- Filed 4 ANDAs with USFDA during the quarter
- Received final approval for 14 ANDAs (of which 1 ANDAs had earlier received tentative approval, now received final approval) during the quarter
- As on 30th June 2025, on a cumulative basis, the company has filed 865 ANDAs with USFDA and received 704 final approvals and 29 tentative approvals
- The company has launched 15 products during the quarter

Europe Formulations

- Europe revenue increased by 18.0% YoY to INR 2,338 Cr driven by robust performance across all key markets; and accounted for 29.7% of consolidated revenue
- In Euro terms, revenue increased by 15.0% YoY to EUR 241 million

Growth Markets Formulations

- Growth Markets formulations revenue increased by 8.8% YoY to INR 772 Cr driven by good performance in key markets; and accounted for 9.8% of consolidated revenue
- In USD terms, revenue increased by 6.1% YoY to USD 90 million
- Domestic formulation sales for the quarter stood at INR 71 Cr

ARV Formulations

- ARV business revenue increased by 55.2% YoY to INR 355 Cr accounting for 4.5% of consolidated revenue
- In USD terms, revenue increased by 51.3% YoY to USD 41 million

Active Pharmaceutical Ingredients (API)

- API revenues decreased by 16.1% Y-o-Y to INR 916 Cr contributing to 11.6% of consolidated revenue
- In USD terms, revenue decreased by 18.2% to USD 107 million

Global Regulatory Filings

Details	Q1FY26	Cumulative Filings as on 30 th Jun 2025
US ANDAs (including filings from Aurobindo USA)	4	865
US DMFs (including filings from Eugia and Auro Peptides)	1	310
Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)	61	4,686
API filings in other key regulated markets (incl. multiple registrations)	39	4,030

Final USFDA Approvals Received in Q1FY26

Received by Aurobindo Pharma Limited

#	Product	Strength	Therapy area
1	Dabigatran Etexilate Capsules (FTF)	75 mg, 110 mg and 150 mg	Cardiovascular
2	Rivaroxaban Tablets (FTF)*	2.5 mg, 10 mg, 15 mg and 20 mg	Cardiovascular
3	Varenicline Tablets	0.5 mg and 1 mg	Smoking Cessation Agent
4	Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets USP (OTC)	180 mg/240 mg	Anti-Histamine
5	Dasatinib Tablets	20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg	Oncology
6	Sapropterin Dihydrochloride Tablets	100 mg	Phenylalanine Hydroxylase Activator
7	Chlorpromazine Hydrochloride Tablets USP	10 mg, 25 mg, 50 mg, 100 mg and 200 mg	Central Nervous System
8	Dapsone Gel	5%	Anti-Infective
9	Acetazolamide Tablets USP	125 mg and 250 mg	Cardiovascular & Central Nervous System
10	Allopurinol Tablets USP	100 mg and 300 mg	Anti-Gout
11	Esomeprazole Magnesium for Delayed-Release Oral Suspension	5 mg, 20 mg and 40 mg	Gastrointestinal
12	Esomeprazole Magnesium for Delayed-Release Oral Suspension	10 mg	Gastrointestinal
13	Ibuprofen and Famotidine Tablets	800 mg/26.6 mg	Pain Relief and Gastrointestinal
14	Oxcarbazepine Extended-Release Tablets	150 mg, 300 mg and 600 mg	Central Nervous System

* ANDAs previously tentatively approved has now received final approval in Q1 FY26

Q1FY26 Earnings Call Details

The company will host earnings call at **8.30 AM IST on 5th August 2025**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: <https://bit.ly/4lQ8NCA>

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 31 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

For further information, please contact:

Investor Relations | Corporate Communications

Phone: 040-66721211

Email: ir@aurobindo.com